Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5

Sonata Šaulytė Trakymienė; Marina Economou; Gili Kenet; Andrea Landorph; Chunduo Shen; Susan Kearney

doi:10.1111/jth.15036

journal article Open Access Sep 01, 2020

Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5

Sonata Šaulytė Trakymienė Marina Economou

Gili Kenet

Andrea Landorph Chunduo Shen Susan Kearney

Journal of Thrombosis and Haemostasis Vol. 18 pp. 15-25 · Elsevier BV

View at Publisher Save 10.1111/jth.15036

Topics

No keywords indexed for this article. Browse by subject →

References

11

[1]

Manco‐Johnson "Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia" N Engl J Med (2007) 10.1056/nejmoa067659

[2]

Srivastava "Treatment Guidelines Working Group on Behalf of The World Federation Of Haemophilia. Guidelines for the management of hemophilia" Haemophilia (2013) 10.1111/hae.12074

[3]

Tiede "Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A" J Thromb Haemost (2013) 10.1111/jth.12161

[4]

Meunier "Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8‐GP) in paediatric patients with severe haemophilia A" Thromb Haemost (2017) 10.1160/th17-03-0166

[5]

Kearney "Health‐related quality‐of‐life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8‐GP): a new recombinant extended half‐life FVIII" Patient Prefer Adherence (2019) 10.2147/ppa.s196103

[6]

Giles Thromb Haemost (1998) 10.1055/s-0037-1615080

[7]

Blanchette J Thromb Haemost (2014) 10.1111/jth.12672

[8]

Chowdary "Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A" Res Pract Thromb Haemost (2019) 10.1002/rth2.12220

[9]

Young "Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A" J Thromb Haemost (2015) 10.1111/jth.12911

[10]

Mullins "Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A" Haemophilia (2017) 10.1111/hae.13119

[11]

O'Hara "The relationship between target joints and direct resource use in severe haemophilia" Health Economics Review (2018) 10.1186/s13561-018-0185-7

Metrics

18

Citations

11

References

Details

Published: Sep 01, 2020
Vol/Issue: 18
Pages: 15-25
License: View

Authors

S

Sonata Šaulytė Trakymienė

Funding

Novo Nordisk

Cite This Article

Sonata Šaulytė Trakymienė, Marina Economou, Gili Kenet, et al. (2020). Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5. Journal of Thrombosis and Haemostasis, 18, 15-25. https://doi.org/10.1111/jth.15036

Long‐term safety and efficacy of N8‐GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5

You May Also Like